Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
10 Health Care Stocks With Whale Alerts In Today's Session
Sangamo Therapeutics Analyst Ratings
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
CRISPR Therapeutics Analyst Ratings
Vertex Upgraded to Buy by Jefferies on Fundamentals, Pipeline
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Beam Therapeutics Analyst Ratings
Vertex Reports Positive Long-term Data for Casgevy
Editas Medicine Presents Data From RUBY Trial At ASH 2024, Showing Reni-Cel Achieves 96% VOE-Free Rate, Sustained Increases In Hemoglobin And Fetal Hemoglobin, And Clinically Meaningful Pain And Function Improvements In Severe Sickle Cell Patients;...
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Agilent Technologies Analyst Ratings
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Vertex Pharmaceuticals Analyst Ratings
Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
Executive Reshuffles: INTC, ZS, ETSY and SEDG
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
Weekly Buzz: Now THOSE are records!!
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025